Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Liver Histology01:27

Liver Histology

The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An imbalance between CD80 and CD86 levels and CD4 regulatory T cell number and transendocytosis function exists in the liver in autoimmune hepatitis.

Clinical and experimental immunology·2026
Same author

Thyroid function and liver fibrosis: FT3 levels are inversely and independently correlated with enhanced liver fibrosis score in solid organ transplant patients with dysglycemia.

Frontiers in immunology·2026
Same author

iRhom2 regulates HMGB1 secretion to modulate inflammation and hepatocyte senescence in an in vitro model of ischemia-reperfusion injury.

Cell death & disease·2026
Same author

Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot study.

Scientific reports·2025
Same author

Normothermic Machine Perfusion and Inflammatory Mediators Adsorption: First Kidney Transplant Experience.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2025
Same author

Practice in evaluating solid organ transplant candidates and recipients with neurological impairment: The European Academy of Neurology neurocritical care panel survey.

European journal of neurology·2025
Same journal

Needle-based confocal laser endomicroscopy and artificial intelligence in pancreatic cystic lesions: Insights and clinical advances.

Best practice & research. Clinical gastroenterology·2026
Same journal

Evidence-based approach to the diagnosis, management and surveillance of pancreatic cystic lesions: from the guidelines to the clinical practice.

Best practice & research. Clinical gastroenterology·2026
Same journal

Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.

Best practice & research. Clinical gastroenterology·2026
Same journal

Predictive risk models for the diagnosis and cancer progression of pancreatic cysts.

Best practice & research. Clinical gastroenterology·2026
Same journal

Preface.

Best practice & research. Clinical gastroenterology·2026
Same journal

Endoscopic ultrasound-guided treatment of pancreatic lesions.

Best practice & research. Clinical gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Liver cirrhosis.

Massimo Pinzani1, Matteo Rosselli, Michele Zuckermann

  • 1Dipartimento di Medicina Interna, Viale G.B. Morgagni, 85, 50134 Firenze, Italy. m.pinzani@dmi.unifi.it

Best Practice & Research. Clinical Gastroenterology
|April 19, 2011
PubMed
Summary
This summary is machine-generated.

Liver cirrhosis involves fibrosis and abnormal nodules, leading to portal hypertension. Reducing fibrosis is key to managing complications and preventing liver cancer.

More Related Videos

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

Related Experiment Videos

Last Updated: Jun 2, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Liver cirrhosis, a consequence of chronic liver diseases, features fibrosis and architectural distortion.
  • Portal hypertension, stemming from increased intrahepatic resistance and blood flow, is a primary complication.
  • A hepatic venous pressure gradient (HVPG) of 10-12 mmHg marks a transition to decompensated cirrhosis, involving systemic effects.

Purpose of the Study:

  • To elucidate the progression and characteristics of liver cirrhosis.
  • To define the critical threshold for portal hypertension and its systemic implications.
  • To explore the relationship between cirrhosis, inflammation, fibrosis, and hepatocellular carcinoma (HCC) development.

Main Methods:

  • Review of existing literature on liver cirrhosis pathophysiology.
  • Analysis of the correlation between liver tissue modifications and portal hypertension.
  • Examination of factors contributing to disease progression and HCC emergence.

Main Results:

  • Cirrhosis involves fibrosis and nodule formation, leading to portal hypertension.
  • HVPG ≥10-12 mmHg indicates a critical stage where liver disease becomes systemic.
  • Chronic inflammation and fibrosis in cirrhosis create a pro-HCC environment.

Conclusions:

  • Antifibrotic therapy in cirrhosis should aim to reduce fibrosis, improve portal hypertension, and decrease HCC risk.
  • The irreversibility of cirrhosis, morphologically or functionally, remains unclear.
  • Understanding fibrosis regression determinants is crucial for effective antifibrotic strategies.